Nektar Therapeutics
Nektar Therapeutics, a leading biopharmaceutical company headquartered in the United States, focuses on innovative drug development to address unmet medical needs. Founded in 1990, Nektar has made significant strides in the industry, particularly in the fields of oncology, immunology, and pain management. The company is renowned for its proprietary drug delivery technologies, which enhance the efficacy and safety of therapeutic agents. Nektar's core products, including its advanced therapies for cancer and chronic pain, stand out due to their unique mechanisms of action and patient-centric design. With a strong market position, Nektar Therapeutics has achieved notable milestones, including strategic partnerships and a robust pipeline of clinical candidates, solidifying its reputation as a pioneer in the biopharmaceutical landscape.
DitchCarbon Score
How does Nektar Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nektar Therapeutics's score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nektar Therapeutics's reported carbon emissions
Nektar Therapeutics, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Nektar Therapeutics has not established any science-based targets or commitments to reduce emissions, nor does it inherit any emissions data from a parent company. This lack of publicly available information suggests that the company may still be in the early stages of developing its climate strategy and emissions reporting framework. In the broader context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. Nektar Therapeutics may benefit from aligning with industry standards and practices to enhance its environmental commitments in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nektar Therapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
